Xintela AB Asset Resilience Ratio
Xintela AB asset resilience ratio. Xintela AB (XINT) has an Asset Resilience Ratio of 37.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Xintela AB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Xintela AB (2016–2024)
Asset resilience ratio of Xintela AB from 2016 to 2024. This chart shows how Xintela AB's Asset Resilience Ratio has changed over time. Read Xintela AB (XINT) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Xintela AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Xintela AB asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr3.38 Million | 37.25% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr3.38 Million | 37.25% |
Asset Resilience Insights
- Very High Liquidity: Xintela AB maintains exceptional liquid asset reserves at 37.25% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Xintela AB Industry Peers by Asset Resilience Ratio
Compare Xintela AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Xintela AB Asset Resilience Ratio by Year (2016–2024)
Xintela AB asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Xintela AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 67.26% | Skr16.68 Million ≈ $1.80 Million |
Skr24.80 Million ≈ $2.67 Million |
+24.81pp |
| 2023-12-31 | 42.45% | Skr7.81 Million ≈ $840.37K |
Skr18.39 Million ≈ $1.98 Million |
+8.42pp |
| 2022-12-31 | 34.03% | Skr8.34 Million ≈ $897.84K |
Skr24.52 Million ≈ $2.64 Million |
-14.38pp |
| 2021-12-31 | 48.41% | Skr11.98 Million ≈ $1.29 Million |
Skr24.74 Million ≈ $2.66 Million |
-20.85pp |
| 2020-12-31 | 69.26% | Skr33.60 Million ≈ $3.62 Million |
Skr48.51 Million ≈ $5.22 Million |
+66.85pp |
| 2019-12-31 | 2.41% | Skr412.00K ≈ $44.34K |
Skr17.09 Million ≈ $1.84 Million |
-60.74pp |
| 2018-12-31 | 63.16% | Skr31.40 Million ≈ $3.38 Million |
Skr49.71 Million ≈ $5.35 Million |
-13.49pp |
| 2017-12-31 | 76.65% | Skr21.91 Million ≈ $2.36 Million |
Skr28.59 Million ≈ $3.08 Million |
-2.93pp |
| 2016-12-31 | 79.58% | Skr18.98 Million ≈ $2.04 Million |
Skr23.85 Million ≈ $2.57 Million |
-- |
About Xintela AB
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indicati… Read more